[ Inside the business ]

WST stock analysis

WST · West Pharmaceutical Services Inc

Surgical and medical instruments and apparatus. Growing 9%. Keeps 23¢ of every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 3.2× sales in 5 yrs. Evidence: sales +9% · 23¢ profit/$1.

01 What's priced in?3.2× sales in 5 yrs
Sales now$3.4B
Needed in 5 yrs$11.0B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Biologics Customers: 40% of sales
Biologics Customers 40%Pharma Customers 24%Contract Manufactured Customers 19%Generics Customers 17%Everyone else
Prepaid $44MSales +9%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Keeps 23¢ per $1
'21'22'23'24'2523¢
Before running costs: 39% → 36%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares −1.7%/yrDebt $203M
07 What could break it?2 to watch
  • Growth slowing
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +21%, +14%, then +9% vs. a year ago.

What could go wrong

Few warning signs.

It has moved 1.1× the market. In the 2022 rate shock it fell 47% while the market fell 24%. Debt is covered by cash.

Speculative check

Self-funding.

Passes every condition: profitable, cash-generating and financially sound.

What they sell

83% Proprietary Products.

Proprietary Products 83% · West Vantage Segment 17% (latest quarter)

Where each dollar goes

23¢ profit.

62¢ to make what it sells, 15¢ on research and overhead, 23¢ left over. Revenue $3.4B in the last 12 months.

Its market

0.3× the economy.

The government expects its industry, fabricated metal product manufacturing, to grow 0.7% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Maturity.

It earns cash, still invests, and pays back more than it borrows.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators. Cash covers 102¢ of each $1 of profit.

Competitive advantage

10 of 10 years.

Returns beat its 9.8% cost of capital in 10 of the last 10 years. Gross margin went from 33% to 36%.

Future bets

2% on research.

$76M a year on R&D. $201M on equipment and buildings.

All figures from West Pharmaceutical Services Inc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.